☆ 4.8 Article

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Claudia A. Salinas et al.

Summary: This study aimed to evaluate the safety of baricitinib compared to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. The results showed an increased risk of venous thromboembolism (VTE) with baricitinib compared to TNFi treatment. Although the risk was slightly higher for major adverse cardiovascular events (MACE) and serious infection, the point estimates varied.

RHEUMATOLOGY AND THERAPY (2023)

Add to Collection

Article Rheumatology

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis

Viktor Molander et al.

Summary: Patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi) have a higher incidence of venous thromboembolism (VTE) compared to those treated with other biological disease modifying antirheumatic drugs (bDMARDs), especially in terms of pulmonary embolism (PE).

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Farzin Khosrow-Khavar et al.

Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Review Rheumatology

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

Yoshiya Tanaka et al.

Summary: This Review discusses the therapeutic use of Janus kinase inhibitors in autoimmune rheumatic diseases, highlighting their disease-specific mechanisms of action. JAK inhibitors suppress intracellular signaling mediated by multiple cytokines, offering potential treatment options for a range of immune and inflammatory disorders.

NATURE REVIEWS RHEUMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg et al.

Summary: In this trial comparing the use of tofacitinib with a TNF inhibitor in a cardiovascular risk-enriched population, the risks of major adverse cardiovascular events (MACE) and cancers were found to be higher with tofacitinib, and it did not meet noninferiority criteria. Several adverse events were more common with tofacitinib.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Rheumatology

Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study

Rishi J. Desai et al.

Summary: There was no significant difference in the risk of venous thromboembolism between patients with rheumatoid arthritis treated with tofacitinib and those treated with TNFα inhibitors.

RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Oral surveillance and JAK inhibitor safety: the theory of relativity

Kevin L. Winthrop et al.

Summary: The published results of the post-marketing ORAL Surveillance study have led to changes in the recommendations for the use of JAK inhibitors. New safety signals for tofacitinib, including malignancy and cardiovascular disease, have emerged relative to TNF blockers. However, the overall data suggest that JAK inhibitors can be used safely at approved doses by many rheumatoid arthritis patients.

NATURE REVIEWS RHEUMATOLOGY (2022)

Add to Collection

Review Rheumatology

Global epidemiology of rheumatoid arthritis

Axel Finckh et al.

Summary: Rheumatoid arthritis is a systemic autoimmune disease that mainly affects joints. The prevalence of RA varies globally, with higher rates in industrialized countries possibly due to environmental and genetic factors. Understanding the natural history of RA and its risk factors in specific populations may lead to prevention strategies.

NATURE REVIEWS RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

Sae Ochi et al.

Summary: This study compared the responsiveness to various biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with difficult-to-treat rheumatoid arthritis. The results suggest that JAK inhibitors are a preferable treatment choice for this type of patients.

ARTHRITIS RESEARCH & THERAPY (2022)

Add to Collection

Review Rheumatology

EULAR definition of difficult-to-treat rheumatoid arthritis

Gyorgy Nagy et al.

Summary: The Task Force aimed to create recommendations for the underserved patient group with difficult-to-treat rheumatoid arthritis by drafting a definition based on international survey data among rheumatologists, nurses, health professionals, and patients. The definition includes specific criteria for treatment failure and symptom characteristics that are considered problematic by both the healthcare provider and the patient. This proposed EULAR definition can be applied in clinical practice, trials, and serve as a foundation for future research.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis

Anthony James Ocon et al.

Summary: The study found that initiating glucocorticoids in steroid-naive RA patients is associated with an increased risk of cardiovascular events, especially at daily doses of >= 5mg, cumulative doses exceeding 1100mg, and durations longer than 81 days. No increased risk was found at lower doses or shorter durations.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)

Frank L. J. Visseren et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Rheumatology

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry

Joel M. Kremer et al.

Summary: This study compared 5-year adverse event incidence rates between tofacitinib and bDMARD initiators in a US registry, finding similar rates for major adverse cardiovascular events, serious infection events, malignancies, death, and venous thromboembolic events, but significantly higher rates of herpes zoster in the tofacitinib group.

ACR OPEN RHEUMATOLOGY (2021)

Add to Collection

Review Rheumatology

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis

Thomas R. Riley et al.

Summary: Immunomodulatory therapy for rheumatoid arthritis carries infectious complications risk. Different therapeutic options have varying risk levels, with TNF inhibitors showing an increase in serious infections risk. Other biological agents and JAK inhibitors have similar risk levels, with JAK inhibitors also associated with higher risk of herpes zoster.

RMD OPEN (2021)

Add to Collection

Article Rheumatology

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC/AHA Risk Calculator

Bengt Wahlin et al.

JOURNAL OF RHEUMATOLOGY (2019)

Add to Collection

Article Rheumatology

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Peter C. Taylor et al.

ARTHRITIS & RHEUMATOLOGY (2019)

Add to Collection

Review Rheumatology

The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference

Fabrizio Conti et al.

RHEUMATOLOGY (2018)

Add to Collection

Article Rheumatology

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis

Neil A. Accortt et al.

ARTHRITIS CARE & RESEARCH (2018)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Management of Rheumatoid Arthritis A Review

Daniel Aletaha et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Medicine, General & Internal

The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthritis

Salaffi Fausto et al.

SWISS MEDICAL WEEKLY (2018)

Add to Collection

Review Rheumatology

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

R. Agca et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Add to Collection

Article Hematology

Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH

C. Kearon et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)

Add to Collection

Review Medicine, General & Internal

Rheumatoid arthritis

Josef S. Smolen et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

Steven E. Nissen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Rheumatology

Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events

D. H. Solomon et al.

ARTHRITIS & RHEUMATOLOGY (2015)

Add to Collection

Article Rheumatology

Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis A Consortium of Rheumatology Researchers of North America Registry Study

D. H. Solomon et al.

ARTHRITIS & RHEUMATOLOGY (2015)

Add to Collection

Article Rheumatology

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

Maxime Dougados et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

Add to Collection

Article Rheumatology

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis

Karen Au et al.

ANNALS OF THE RHEUMATIC DISEASES (2011)

Add to Collection

Article Rheumatology

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

E Baecklund et al.

ARTHRITIS AND RHEUMATISM (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.